Quince Therapeutics (QNCX) Asset Writedowns and Impairment (2022 - 2026)
Quince Therapeutics (QNCX) posted quarterly Asset Writedowns and Impairment of $67.8 million for Q1 2026, up 102639.39% quarter-over-quarter from $66000.0 in Q1 2023.
Quince Therapeutics (QNCX) Asset Writedowns and Impairment (2022 - 2026) Analysis & Trends
Quince Therapeutics' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $67.8 million for Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $67.8 million; the TTM figure through Mar 2026 stood at $67.8 million (changed N/A YoY), while the FY2023 annual figure was $66000.0, down 51.47% from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at $67.8 million, up from $66000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $67.8 million in Q1 2026, with the low at $38000.0 in Q3 2022.
- The 3-year median for Asset Writedowns and Impairment is $66000.0 (2023), against an average of $22.6 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.81 Mn |
| Mar 31, 2026 | 67.81 Mn |
| Mar 31, 2023 | 66,000.00 |
| Mar 31, 2023 | 66,000.00 |
| Sep 30, 2022 | 38,000.00 |
| Sep 30, 2022 | 38,000.00 |